First Patient Enrolled in Ph 3 Trial of Ivonescimab + Ligufalimab for 1L Treatment of HNSCC Compared to Pembrolizumab November 5, 2024
First Patient Enrolled in Ph 3 Trial of Ivonescimab Combination as 1L Therapy for Biliary Tract Tumors, Compared to Durvalumab November 5, 2024
Three Ph 3 Trials of Datopotamab Deruxtecan-Based Combinations Initiated in Patients with Advanced Nonsquamous NSCLC November 5, 2024
First Patient Dosed in Ph 3 Study Evaluating RMC-6236 in Previously Treated Patients with Metastatic Pancreatic Ductal Adenocarcinoma October 29, 2024
First Patient Dosed in Clinical Collaboration Evaluating HC-7366 in Combination with WELIREG® (belzutifan) in patients with advanced ccRCC October 29, 2024
Unrestricted Enrollment of Patients on Decoy20 Weekly Dosing Based on Encouraging Safety Data Initiated October 22, 2024
First Patient Dosed in Ph 1/2 Cell Therapy Trial of TAC101-CLDN18.2 for the Treatment of Claudin 18.2+ Solid Tumors October 22, 2024
First Patient dosed in Ph 1/2a Clinical Trial of BPT567 in patients with solid tumors October 22, 2024
35 sites active and enrolling in pivotal Ph 3 study of Bria-IMT™ combination with immune check point inhibitor in metastatic breast cancer (MBC) October 22, 2024
First Patient Dosed in Ph 1/2 Trial of PFL-241/STX-241 in Locally Advanced or Metastatic NSCLC patients October 15, 2024
Ph 3 SunRISe-2 trial in MIBC patients discontinued for not showing superiority versus chemoradiation October 15, 2024
First patient enrolled in Ph 1/2a clinical trial for Lenti-HPV07 against oropharyngeal and cervical cancers October 15, 2024
BDTX-1535 program to be advanced into pivotal development based on robust Ph 2 clinical data from EGFRm NSCLC patients October 15, 2024
First Patient Dosed in Ph 2 Clinical Trial of Radspherin® in Ovarian Cancer Patients October 15, 2024
First Patient Dosed in Ph 3 Clinical Trial of UGN-103 in patients with Low-Grade Intermediate-Risk NMIBC October 8, 2024
First Patient Dosed in Ph 1b Trial, MELODY-1 of MB097 Precision Microbiome Co-Therapy in Advanced Melanoma October 8, 2024
